Circulating Epstein–Barr virus DNA and high‐risk extra‐nodal involvement identify disease‐specific mortality in post‐transplant lymphoproliferative disorder
British Journal of Haematology · 05.11.2026
DOI: 10.1111/bjh.70941 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 05.11.2026. Verfasst von Yong-Pyo Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Ministry of Health and Welfare, National Research Foundation, Korea Health Technology R&D Project.
Abstract (Originalsprache)
Post‐transplant lymphoproliferative disorder (PTLD) is a heterogeneous disorder arising in the context of immunosuppression after solid organ transplantation. Determinants of PTLD‐specific mortality remain poorly defined, as conventional survival analyses may not adequately capture disease‐attributable risk given substantial competing mortality. We performed a retrospective analysis of 75 solid organ transplant recipients with PTLD, using a competing‐risk framework with Fine–Gray subdistribution hazard regression to identify factors associated with PTLD‐related death, accounting for non‐PTLD mortality. Over a median follow‐up of 71.0 months, 35 patients (46.7%) died, of whom 25 (71.4%) experienced PTLD‐related death. After adjustment for International Prognostic Index (IPI), high‐risk extra‐nodal involvement (bone marrow or central nervous system) remained associated with PTLD‐related mortality (subdistribution hazard ratio [sHR], 3.82; 95% confidence interval [CI], 1.67–8.73; p = 0.001), as did detectable circulating Epstein–Barr virus (EBV) deoxyribonucleic acid (DNA) (sHR, 4.38; 95% CI, 1.63–11.76; p = 0.003). Combined tissue and blood EBV stratification further revealed a hierarchical mortality gradient across four EBV‐defined subgroups (dual‐positive to dual‐negative). High‐risk extra‐nodal involvement and detectable circulating EBV DNA are independently associated with PTLD‐attributable mortality after adjustment for IPI. Combined tissue and circulating EBV assessment may provide complementary prognostic information. Prospective validation in larger multicentre cohorts is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
- Division of Transplantation Surgery, Samsung Medical Center, Department of Surgery, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Samsung Medical Center, Department of Pathology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Yong-Pyo Lee, Jae Berm Park, Nayoung Han, Young Hyeh Ko, Sang Eun Yoon
Förderung
- Ministry of Health and Welfare
- National Research Foundation
- Korea Health Technology R&D Project
Zitieren
APA
Lee, Y. P., Lee, K. W., Park, J. B., Han, N., Ko, Y. H., Kim, S. J., Kim, W. S., & Yoon, S. E. (2026). Circulating Epstein–Barr virus DNA and high‐risk extra‐nodal involvement identify disease‐specific mortality in post‐transplant lymphoproliferative disorder. British Journal of Haematology. https://doi.org/10.1111/bjh.70941
Vancouver
Lee YP, Lee KW, Park JB, Han N, Ko YH, Kim SJ, et al. Circulating Epstein–Barr virus DNA and high‐risk extra‐nodal involvement identify disease‐specific mortality in post‐transplant lymphoproliferative disorder. British Journal of Haematology. 2026. doi:10.1111/bjh.70941
BibTeX
@article{Lee2026,
author = {Lee, Yong-Pyo and Lee, Kyo Won and Park, Jae Berm and Han, Nayoung and Ko, Young Hyeh and Kim, Seok Jin and Kim, Won Seog and Yoon, Sang Eun},
title = {Circulating Epstein–Barr virus DNA and high‐risk extra‐nodal involvement identify disease‐specific mortality in post‐transplant lymphoproliferative disorder},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70941}
}
EUVIMED